Posters

The effect of low dose aspirin on tear osmolarity, Schirmer and break-up time scores

Poster Details

First Author: S.Samet Ermis TURKEY

Co Author(s):    A. Yazici   E. Sogutlu Sari   G. Sahin   T. Gurbuzer   N. Tiskaoglu        

Abstract Details

Purpose:

To compare the schirmer, tear break-up time (TBUT), tear osmolarity and ocular surface vital dye staining scores of low dose aspirin users (antiaggregant) with control group.

Setting:

Prospective, randomized, controlled trial Twenty four patients who were followed up in cardiology department and use aspirin (Coraspin 100 mg, Bayer HealthCare AG, Germany) for antiaggregant purposes and 24 controls who required antiaggregant treatment but not started yet were included to the study.

Methods:

Age, gender, systemic disorders, and medications that patients use were noted. Participants with any ocular surface disorder, previous ocular surgery, previous dry eye diagnosis, any topical ophthalmic medication or contact lens use were excluded. ocular surface disease index questionnaire (OSDI) and the dry eye parameters with the order of tear osmolarity, TBUT, schirmer and oxford grading of ocular surface staining were performed in the morning time.

Results:

The groups were age and gender matched (p=0.88 and p=0.77 respectively). The mean aspirin use was 9.21±5.82 years in the aspirin use group. The mean osmolarity was 307.79±15.02 mOsm/L in the aspirin group and was 319.29±21.00 mOsm/L in the control group. The mean schirmer score was 19.42±11.27 mm and 18.87±11.84 mm, TBUT was 12.00±3.39 and 11.92±4.41 seconds, OSDI score 21.75±16.65 and 30.11±21.97 and oxford score was 0.21±0.41 and 0.25±0.60 in aspirin and control group respectively. The differences were not significant in any parameter (p>0.05).

Conclusions:

Although not statistically significant, tear osmolarity was lower in aspirin group. Further large scaled studies are needed to reach a better conclusion.

Financial Disclosure:

NONE